Literature DB >> 11737993

High-performance liquid chromatography assay of amiodarone in rat plasma.

A S Jun1, D R Brocks.   

Abstract

PURPOSE: A high-performance liquid chromatographic method is described for the determination of amiodarone in rat plasma.
METHODS: After liquid-liquid extraction, the separation of amiodarone from internal standard and endogenous components was accomplished using reversed phase chromatography. The mobile phase, a combination of monobasic potassium phosphate, methanol and acetonitrile, was run isocratically through a C(8) analytical column. The UV detection was at 254 nm for ethopropazine, the internal standard, and subsequently changed to 242 nm for amiodarone detection.
RESULTS: Analytical run time was less than 13 min. Mean recovery was 75% and 82% for lower (0.5 microg/ml) and higher concentrations (5 microg/ml), respectively. The assay exhibited excellent linear relationships between peak height ratios and plasma concentrations; quantitation limit was at least 0.035 microg/ml, based on 100 microl of rat plasma. Accuracy and precision were <17% over the concentration range of 0.035 to 5 microg/ml. CONCLUSION. The assay was applied successfully to the measurement of amiodarone plasma concentrations in rats given the drug orally.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737993

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  2 in total

1.  Effect of Lactobacillus casei on the Pharmacokinetics of Amiodarone in Male Wistar Rats.

Authors:  Zuzana Matuskova; Pavel Anzenbacher; Rostislav Vecera; Michal Siller; Helena Tlaskalova-Hogenova; Jan Strojil; Eva Anzenbacherova
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

2.  Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats.

Authors:  Zuzana Matuskova; Eva Anzenbacherova; Rostislav Vecera; Helena Tlaskalova-Hogenova; Milan Kolar; Pavel Anzenbacher
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.